News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

PaxVax, Inc. Announces Positive Results for Oral Ad4 Vaccine Technology



1/31/2013 10:29:45 AM

MENLO PARK, Calif.--(BUSINESS WIRE)--PaxVax, Inc., which develops and commercializes innovative vaccines against infectious diseases in a socially responsible manner, today announced positive results in a Phase 1 clinical trial for its oral, replicating adenovirus serotype 4 (Ad4) vector vaccine for H5N1 (avian flu). The results have been published in the journal Lancet Infectious Diseases (published online January 29, 2013). The study was funded by The Wellcome Trust.

Read at BioSpace.com


comments powered by Disqus
   
Bird Flu

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES